Summary
Metoprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atopic Dermatitis (Eczema) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atopic Dermatitis (Eczema). ClinicalTrials.gov lists 5 registered trials linking Metoprolol to Atopic Dermatitis (Eczema): 5 have completed. The most advanced is Phase 2 (NCT04562116). The largest enrolment is 40 participants (NCT03556592). Registration activity spans 2015 to 2024. No published literature item is linked to Metoprolol and Atopic Dermatitis (Eczema) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Atopic Eczema ranks 294 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent; moderate-severe adult AD: <15% spontaneous clearance at 5 years.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 35.5 (trials 15.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 5 total: 0 recruiting, 0 active / not yet recruiting, 5 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
| Linked via biomarker / target | AFF1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT04562116 | A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis 2021 | completed | Phase 2 | 17 |
| NCT06686628 | An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates 2024 | completed | Phase 1 | 23 |
| NCT02647086 | Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) 2015 | completed | Phase 1 | 14 |
| NCT03556592 | Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 2018 | completed | Phase 1 | 40 |
| NCT05891119 | Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis 2023 | completed | Early Phase 1 | 21 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target AFF1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Metoprolol approved for Atopic Dermatitis (Eczema)?
Metoprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atopic Dermatitis (Eczema) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atopic Dermatitis (Eczema). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Metoprolol in clinical trials for Atopic Dermatitis (Eczema)?
ClinicalTrials.gov lists 5 registered trials linking Metoprolol to Atopic Dermatitis (Eczema): 5 have completed. The most advanced is Phase 2 (NCT04562116). The largest enrolment is 40 participants (NCT03556592). Registration activity spans 2015 to 2024.
What does the evidence show for Metoprolol in Atopic Dermatitis (Eczema)?
Metoprolol has 5 completed registered trials for Atopic Dermatitis (Eczema) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target AFF1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.